Suche
Mein Konto
Biotech expert Jens Lion scores +71% without Nvidia: A look at the future in the biotech sector in 2024.
Jens Lion achieved an impressive +71% return for No Brainer Club last year without relying on the AI hype or Nvidia. Find out more in the exciting interview! 📈🤓 #BiotechExpert #StockMarket #Investing
Biotech expert Jens Lion scores +71% without Nvidia: A look at the future in the biotech sector in 2024.
Performance in the biotech sector
The biotech sector posted a strong performance in December, leading to low expectations for the following month. Nevertheless, significant gains were made, particularly in stocks that had previously been in a state of slumber. Larger biotech companies that had already shown strong performances were under pressure. In contrast, small caps and low-cap stocks performed with a delay, but with significantly stronger momentum within a few days.
Outlook for 2024 in the biotech sector
Expectations for 2024 are mixed. The distortions and opportunities in the biotech and small-cap segment remain great. There is some short-term danger due to the euphoria surrounding interest rate cuts, but this should be leveled out. Given the favorable valuation level for small caps, an optimistic attitude is evident. Despite the volatility associated with the US election campaign, positive developments are expected in the long term.
Positioning the No Brainer Club for the coming months
After the rally of the past few weeks, profits were realized but investments were maintained. Even in a difficult market environment, there are still attractive investment opportunities, especially outside of the broad markets. The No Brainer Club reacts flexibly to market opportunities and invests without rigid guidelines. Confidence for 2024 remains high as attractive opportunities still exist despite the biotech sector calming down.